Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors JACC State-of-the-Art Review

被引：77

作者：

Zelniker, Thomas A. ^{[1
,2
,3
]}

Braunwald, Eugene ^{[1
,2
,3
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, Boston, MA 02115 USA

[2] Harvard Med Sch, Dept Med, Boston, MA 02115 USA

[3] Med Univ Vienna, Vienna Gen Hosp, Div Cardiol, Vienna, Austria

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 75卷 / 04期

关键词：

cardiorenal interaction; diabetes; heart failure; renal function; sodium-glucose cotransporter 2 inhibitor; CARDIOVASCULAR OUTCOMES; DIABETES-MELLITUS; EMPAGLIFLOZIN; EFFICACY; SAFETY; CANAGLIFLOZIN; DAPAGLIFLOZIN; MORTALITY; RISK; DISEASE;

D O I：

10.1016/j.jacc.2019.11.036

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Changes in the regulatory guidelines by the U.S. Food and Drug Administration and the European Medical Agency requiring large-scale trials that study the cardiovascular safety of new glucose-lowering drugs have improved our understanding of type 2 diabetes mellitus. Unexpectedly, these trials demonstrated that sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes. This second part of this 2-part review summarizes the findings of recent clinical trials and their clinical implications and describes ongoing trials and future areas of research. (C) 2020 by the American College of Cardiology Foundation.

引用

页码：435 / 447

页数：13

共 59 条

[1]

[Anonymous], 1886, CENTRALBLATT MED WIS

[2]

[Anonymous], 2018, DIABETES CARE, DOI DOI 10.1007/S11548-018-1807-61

[3]

Arnett DK, 2019, CIRCULATION, V140, pE563, DOI [10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.009, 10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.010]

[4] Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus [J].

Berg, David D. ;

Wiviott, Stephen D. ;

Scirica, Benjamin M. ;

Gurmu, Yared ;

Mosenzon, Ofri ;

Murphy, Sabina A. ;

Bhatt, Deepak L. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Wilding, John P. H. ;

Johanson, Per ;

Johansson, Peter A. ;

Langkilde, Anna Maria ;

Raz, Itamar ;

Braunwald, Eugene ;

Sabatine, Marc S. .

CIRCULATION, 2019, 140 (19) :1569-1577

[5] Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors A Review of Spontaneous Postmarketing Cases [J].

Bersoff-Matcha, Susan J. ;

Chamberlain, Christine ;

Cao, Christian ;

Kortepeter, Cindy ;

Chong, William H. .

ANNALS OF INTERNAL MEDICINE, 2019, 170 (11) :764-+

[6] Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure Insights From the EMPA-REG OUTCOME Trial [J].

Butler, Javed ;

Zannad, Faiez ;

Fitchett, David ;

Zinman, Bernard ;

Koitka-Weber, Audrey ;

von Eynatten, Maximilian ;

Zwiener, Isabella ;

George, Jyothis ;

Brueckmann, Martina ;

Cheung, Alfred K. ;

Wanner, Christoph .

CIRCULATION-HEART FAILURE, 2019, 12 (06)

[7] Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV) [J].

Cannon, Christopher P. ;

Mcguire, Darren K. ;

Pratley, Richard ;

Dagogo-Jack, Sam ;

Mancuso, James ;

Huyck, Susan ;

Charbonnel, Bernard ;

Shih, Weichung J. ;

Gallo, Silvina ;

Masiukiewicz, Urszula ;

Golm, Gregory ;

Cosentino, Francesco ;

Lauring, Brett ;

Terra, Steven G. .

AMERICAN HEART JOURNAL, 2018, 206 :11-23

[8] Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019 [J].

Cefalu, William T. ;

Berg, Erika Gebel ;

Saraco, Mindy ;

Petersen, Matthew P. ;

Uelmen, Sacha ;

Robinson, Shamera .

DIABETES CARE, 2019, 42 :S90-S102

[9] Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study [J].

Dandona, Paresh ;

Mathieu, Chantal ;

Phillip, Moshe ;

Hansen, Lars ;

Tschoepe, Diethelm ;

Thoren, Fredrik ;

Xu, John ;

Langkilde, Anna Maria .

DIABETES CARE, 2018, 41 (12) :2552-2559

[10] Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial [J].

Dandona, Paresh ;

Mathieu, Chantai ;

Phillip, Moshe ;

Hansen, Lars ;

Griffen, Steven C. ;

Tschope, Diethelm ;

Thoren, Fredrik ;

Xu, John ;

Langkilde, Anna Maria .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (11) :864-876

← 1 2 3 4 5 6 →